pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Parabilis Medicines · news · pharmadog
← back to Parabilis Medicines
News mentioning Parabilis Medicines
49
stories
Aug 6, 26
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
fiercebiotech
Aug 5, 26
‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E
fiercebiotech
Jul 31, 26
Apnimed’s IPO dream comes true with upsized $192M IPO to fund sleep apnea pill launch
fiercebiotech
Jul 24, 26
Scribe reels in nearly $129M in rare early-stage IPO for a gene editing biotech
biospace
Jul 24, 26
Scribe secures $129M in a rare gene editing IPO
biopharma dive
Jul 24, 26
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
fiercebiotech
Jul 20, 26
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
fiercebiotech
Jul 19, 26
Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax
fiercebiotech
Jul 19, 26
Geopolitics ‘chills’ British biotech IPO plans, despite $2B in Q2 VC funds
fiercebiotech
Jul 16, 26
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
biospace
Jul 13, 26
Biotech startup funding gap widens despite rebound in VC investment
biopharma dive
Jun 11, 26
Kardigan plans $320M IPO for heart drugs as Nasdaq listings gain steam
endpoints
Jun 10, 26
Parabilis CEO Mathai Mammen on biotech's record IPO
endpoints
Jun 10, 26
Parabilis sets a record with a $670M biotech IPO
biopharma dive
Jun 10, 26
STAT+: Hope for Kendall Square’s lab market
stat
Jun 9, 26
Lilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drug
endpoints
Jun 4, 26
Parabilis Medicines charts $413M IPO to back peptide pipeline
endpoints
May 18, 26
Regeneron reaches $125M Parabilis deal for hard-to-catch drug targets
endpoints
May 18, 26
Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug
biopharma dive
← prev
page 2 of 2
next →